Alcon announced the closing of its deal to acquire BELKIN Vision with a total upfront consideration of $81 million, including a cash payment of approximately $65 million. The deal also includes the potential for up to $385 million in payments, contingent upon rigorous sales-based milestones, the company said in a press release. The acquisition includes BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology, expanding Alcon’s glaucoma portfolio with a first-line therapy. 

For glaucoma, Alcon also offers implantables, such as Hydrus Microstent, and pharmaceutical drops that are currently available in the United States.

The DSLT technology is approved in the EU and the U.K., and is indicated to perform SLT. The device received 510(k) clearance from the FDA but is not yet available in the United States. With this acquisition, Alcon says it plans to continue to supply DSLT in the EU and U.K. and aims to make the device available to physicians in the United States by the end of 2024. In addition, Alcon says it is also integrating DSLT into its Alcon Vision Suite ecosystem.

Additional information about plans and timing for launches in new markets will be provided in the future.